Omada Health Reports Second Quarter 2025 Results
Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025.
Read Article
Stay up to date with the latest in virtual health and chronic care industry trends and thought leadership through our active blog library. We cover topics on digital health, behavior change, chronic disease management and prevention, and more.
Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025.
Read Article
Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results.
Read Article
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises
Read Article
Become an Omada Insider, subscribe to our monthly newsletter.
Sign me upOmada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a public offering price of $19.00 pe
Read Article
Omada Health announces its initial public offering, offering 7.9 million shares at $18–$20 each, and plans to list on Nasdaq under the ticker symbol “OMDA.”
Read Article
Introducing Omada Health's Nutritional Intelligence with AI-powered OmadaSpark! Experience real-time support to tackle emotional eating & make informed, lasting food choices for a healthier lifestyle
Read Article
Omada Health presented three posters at the Society of Behavioral Medicine's Annual Meeting. New data demonstrates behavioral, mental, and physical health benefits of Omada's cardiometabolic programs.
Read Article
Omada’s Clinical Advisory Board demonstrates its commitment to rigorous clinical evaluation and helps underscore the impact of its behavior change programs
Read Article
In a survey of over 2,000 doctors, a majority believed GLP-1s need to be paired with changes in diet and exercise to be effective in driving healthy weight loss.
Read Article
Real-world data analysis shows Omada members, on average, experienced virtually no weight gain 16 weeks after discontinuing a GLP-1 compared to an average of 6-7% weight gain estimated from trial data
Read Article
Survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals; respondents want to lose an average of 22% more weight.
Read Article
Dr. Beal brings extensive experience in clinical innovation, patient advocacy, and population health to Omada’s Board.
Read Article
Through Alaska’s Fresh Start Campaign, Thousands of Residents Have Access to Omada’s Virtual Prevention, Diabetes, and Hypertension Coaching Programs
Read Article
New board members provide deep clinical and commercial experience.
Read Article
Company pledges to keep humans at the center of care.
Read Article
Join Omada in observing Diabetes Alert Day on March 22, 2024 as we cover the statistics of diabetes and some of the risk factors to watch out for.
Read Article
Findings show that meaningfully engaged Omada members on GLP-1s achieved an average of 1.7 times greater weight loss, and inform a new collaboration with Evernorth's EncircleRx program.
Read Article
Building on more than a decade of insights and 28 peer-reviewed publications, Omada announces plans to develop more learnings focused on the long-term outcomes of GLP-1s on weight health
Read Article
Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support.
Read Article
The new offering will make it easier for Omada’s over 20 million eligible members to discover and enroll in Omada’s cardiometabolic programs.
Read Article
Loading More...